Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Asset Writedowns and Impairment: 2019-2024

Historic Asset Writedowns and Impairment for Akebia Therapeutics (AKBA) over the last 6 years, with Dec 2024 value amounting to $4.2 million.

  • Akebia Therapeutics' Asset Writedowns and Impairment fell 60.51% to $530,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $4.2 million for FY2024, which is 163.00% up from last year.
  • Akebia Therapeutics' Asset Writedowns and Impairment amounted to $4.2 million in FY2024, which was up 163.00% from $1.6 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Asset Writedowns and Impairment registered a high of $114.4 million during FY2020, and its lowest value of $406,000 during FY2022.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $1.6 million (2023), whereas its average is $2.1 million.
  • In the last 5 years, Akebia Therapeutics' Asset Writedowns and Impairment skyrocketed by 1,508.90% in 2020 and then plummeted by 97.30% in 2022.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Asset Writedowns and Impairment stood at $114.4 million in 2020, then plummeted by 86.85% to $15.0 million in 2021, then crashed by 97.30% to $406,000 in 2022, then skyrocketed by 294.09% to $1.6 million in 2023, then surged by 163.00% to $4.2 million in 2024.